While genetic disorders comprising overgrowth and neurological symptoms give a clear rationale for the application of PI3K/mTOR inhibitors in oncology, the prediction of sensitivity or resistance is still subject to discussion and evaluation. The gene discussed is MTOR; the disease is hereditary disease.